Challenging cardiovascular risk in diabetes: ready for a new approach?
This lecture was part of a CME accredited symposium; SGLT2 inhibition, diabetes and CVD: Where does this fit in CV risk management? held at ESc 2016 in Rome
Video navigation menu
- Incidence of diabetes 00:06
- Multifactorial prevention of CV morbidity and mortality 02:51
- Glucose-lowering medication – GLP-1 inhibitor liraglutide in the LEADER trial 07:56
- Glucose-lowering medication – SGLT2 inhibitor empagliflozin in the EMPA-REG OUTCOME trial 08:41
Educational objectives of this symposium were to:
- Summarise the epidemiology and pathophysiology of patients at increased cardiovascular risk and diabetes
- Identify key components of renal glucose handling and the contribution of the kidney to glucose homeostasis
- Describe the effect of multiple interventions that currently are deployed for T2D on cardiovascular safety and the currently unmet need on impacting cardiovascular outcomes-
- Explain, based on scientific evidence, the effects that SGLT2 inhibiting agents may have on cardiometabolic markers, including lipids, weight gain, risk of hypoglycemia, HbA1c, glucose levels, related markers and cardiovascular outcomes
- Discuss current and future strategies for practical management and interventions to prevent cardiovascular events in multi-risk patients
This symposium was accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s).
Professor John Deanfield, MD - Professor of Cardiology - Director, National Centre for Cardiovascular Prevention and Outcomes, University College London, United Kingdom
Supported by an unrestricted educational grant from Boehringer Ingelheim/Lilly.